SCHEMBL2860485

SCHEMBL2860485

O=Cc1cccc2c1C=CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ERN1 O75460 4/20 0.36
ALDH1A1 P00352 2/20 0.34
TRIM24 O15164 2/20 0.34
TRIM33 Q9UPN9 2/20 0.34
TSHR P16473 1/20 0.34
CYP2A6 P11509 1/20 0.32
KCNJ1 P48048 1/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
TLR2 O60603 1/20 0.32
TLR1 Q15399 1/20 0.32
TLR6 Q9Y2C9 1/20 0.32
HPGD P15428 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29561529 1.00 MEN1 (0.41) MEN1LMNATHRBBLMKMT2A
SCHEMBL4405506 0.81 MEN1 (0.38) MEN1LMNATHRBBLMKMT2A
SCHEMBL4403298 0.80 MEN1 (0.34) MEN1LMNATHRBBLMKMT2A
SCHEMBL28757237 0.80 CA1 (0.30) CA1CA2
SCHEMBL7636146 0.80 ALDH1A1 (0.34) ALDH1A1CA1CA2
SCHEMBL23854833 0.80 CA1 (0.30) CA1CA2
SCHEMBL9321463 0.79 CYP3A4 (0.37) ALDH1A1TSHRCYP2A6HPGD
SCHEMBL4445413 0.79 CYP2A6 (0.34) MEN1LMNATHRBBLMKMT2A
SCHEMBL4408085 0.78 LMNA (0.42) MEN1LMNATHRBBLMKMT2A
SCHEMBL6533122 0.74 NFE2L2 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110583573-A Construction and evaluation method of blood deficiency mouse model 山西大学 2019-12-20 CN claimed
US-12077506-B2 Indane derivatives as hypoxia inducible factor-2(α) inhibitors NIKANG THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
US-11952493-B2 Moisture-curing polyurethane composition containing oxazolidine SIKA TECHNOLOGY AG (CH) 2024-04-09 US disclosed
CN-113272299-B Moisture-curable polyurethane compositions comprising oxazolidines SIKA技术股份公司 2023-07-07 CN disclosed
EP-3898619-B1 MOISTURE-CURABLE POLYURETHANE COMPOSITION CONTAINING OXAZOLIDINE SIKA TECH AG (CH) 2023-02-08 EP disclosed
US-20220025176-A1 MOISTURE-CURING POLYURETHANE COMPOSITION CONTAINING OXAZOLIDINE SIKA TECHNOLOGY AG (CH) 2022-01-27 US disclosed
CN-113272299-A Moisture-curing polyurethane composition comprising oxazolidine SIKA技术股份公司 2021-08-17 CN disclosed
EP-3765453-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION Jubilant Prodel LLC (US) 2021-01-20 EP disclosed
CN-112105654-A Curable resin mixture, curable resin composition, and cured product thereof 日本化药株式会社 2020-12-18 CN disclosed
WO-2020031935-A1 CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT 日本化薬株式会社 2020-02-13 WO disclosed
EP-1632291-B1 HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST NISSAN CHEMICAL IND LTD (JP) 2009-12-16 EP disclosed
EP-2106855-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst Nissan Chemical Industries, Ltd. (JP) 2009-10-07 EP disclosed
US-20090082583-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-03-26 US disclosed
EP-1551818-B1 THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORP (US) 2009-02-04 EP disclosed
US-20070093667-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-04-26 US disclosed
EP-1632291-A1 HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST Nissan Chemical Industries, Ltd. (JP) 2006-03-08 EP disclosed
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-12-22 US disclosed
EP-1552828-A1 THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME Nissan Chemical Industries, Ltd. (JP) 2005-07-13 EP disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093667-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst OXGR1, OXER1, OGFOD1 MEN1 3099/4885LMNA 4881/4885THRB 3932/4885
US-12077506-B2 Indane derivatives as hypoxia inducible factor-2(α) inhibitors HIF1AN, HIF1A, NFE2L2 MEN1 4498/4885LMNA 2630/4885THRB 990/4885
US-20090082583-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst OXGR1, OGFOD1, OGDH MEN1 3345/4885LMNA 4878/4885THRB 4020/4885
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same PDGFRA, PTAFR, TBXA2R MEN1 2530/4885LMNA 4099/4885THRB 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.